Amgen 1Q Revenues: $3.2 billion (+14%) 1Q Earnings: $1 billion (+17%) Comments: Worldwide sales of Aranesp increased 24% to $893 million, Epogen sales increased 4% to $604 million and Enbrel sales increased 11% to $658 million. Combined sales of Neulasta and Neupogen, increased 13% to $896 million in the quarter. R&D expenses increased 20% to $624 million in the quarter....